Ivermectin 1% cream is a topical formulation approved by the FDA and EMA for the inflammatory lesions of rosacea. Marketed originally as Soolantra, it is applied once daily to the face and works through a dual mechanism: it kills Demodex mites in the follicles and independently damps down the inflammatory cascade those mites provoke.
People with papulopustular rosacea carry markedly higher densities of Demodex folliculorum mites in their facial follicles than unaffected people. The mites, and the bacteria they carry, trigger an innate immune response involving cathelicidin and toll-like receptor 2 signalling, which produces the papules and pustules characteristic of the condition.
Ivermectin acts on both sides of that loop. It paralyses and kills the mites through the same glutamate-gated chloride channel mechanism it uses systemically, and it independently suppresses the production of inflammatory cytokines. This second effect is why the cream begins to reduce redness before mite counts have fully fallen.
A pea-sized amount is spread thinly across the whole face once daily — forehead, chin, nose and both cheeks — avoiding eyes, lips and the inside of the nostrils. It is applied to clean, dry skin, and most people use it at night.
It is a full-face treatment, not a spot treatment. Applying it only to visible lesions leaves mite populations elsewhere on the face untouched, and the lesions simply reappear in the untreated areas.
Treatment runs for at least 12 weeks before efficacy is judged. Many people continue longer; the pivotal extension studies followed patients for up to a year with a maintained response.
Two identically designed 12-week pivotal trials compared ivermectin 1% cream with vehicle in more than 1,300 patients with moderate to severe papulopustular rosacea. Both showed significantly greater reduction in inflammatory lesion counts and significantly higher rates of clear or almost clear skin on the Investigator Global Assessment.
A head-to-head trial against metronidazole 0.75% cream, published in the British Journal of Dermatology, found ivermectin 1% superior on lesion count reduction at 16 weeks and associated with a longer remission before relapse.
Topical ivermectin is generally well tolerated. Reported effects are local and mostly mild: a burning or stinging sensation, transient dryness, itching and skin irritation, each in a small percentage of users.
A temporary worsening in the first one to three weeks is common and expected. As mites die they release antigenic material that provokes a short-lived inflammatory response. This is not an allergic reaction and not a reason to stop; it typically settles by week four.
For rosacea, topical is the approved and generally preferred route: it delivers high drug concentration exactly where the mites live with negligible systemic absorption.
Oral ivermectin is used for skin conditions where the target is not confined to the face — scabies across the whole body, crusted scabies, or severe Demodex infestation in immunocompromised patients — and is sometimes combined with topical treatment. See ivermectin for rosacea and Demodex blepharitis.
GMP-certified human formulations — tablets and 1% cream. Never veterinary products. Most USA orders ship within 1–7 business days, with tracking on every order.
View products and pricingMost people see measurable improvement by week four, with the full effect at 12 weeks. Trials assessed the primary endpoint at 12 weeks, and improvement continued in extension studies beyond that. A brief worsening in the first one to three weeks is normal.
Soolantra is the original brand name for ivermectin 1% cream. Generic versions contain the same active ingredient at the same concentration. Vehicle formulation can differ slightly between manufacturers, which occasionally affects tolerability but not the active drug.
It is designed for once-daily use, and extension studies have followed continuous use for up to a year without new safety signals. Long-term use should still be reviewed periodically with a clinician.
It is approved for inflammatory lesions — papules and pustules. Background redness and visible blood vessels often improve as inflammation settles, but persistent facial redness and telangiectasia respond better to other treatments such as brimonidine or laser therapy.
Combinations are common in practice, including with azelaic acid or oral doxycycline for more severe disease. Layering multiple topical actives can increase irritation, so sequencing should be agreed with a dermatologist.